{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:21:45Z","timestamp":1792012905669,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40744-025-00820-3","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T15:27:48Z","timestamp":1766762868000},"page":"265-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS)"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05252533","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Edwin","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Berezny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey J.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen G.","family":"Lomax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia G.","family":"Liva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Z.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara Wine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruy","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Imundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Majlessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-6512","authenticated-orcid":false,"given":"Jocelyn H.","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the U-POPS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Reyhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"820_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"key":"820_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3899\/jrheum.180131","volume":"94","author":"D Zisman","year":"2018","unstructured":"Zisman D, Stoll ML, Aviel YB, Mellins ED. Juvenile psoriatic arthritis: a report from the GRAPPA 2017 annual meeting. J Rheumatol. 2018;94:11\u20136.","journal-title":"J Rheumatol"},{"key":"820_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.884727","volume":"10","author":"F Brunello","year":"2022","unstructured":"Brunello F, Tirelli F, Pegoraro L, et al. New insights on juvenile psoriatic arthritis. Front Pediatr. 2022;10:884727.","journal-title":"Front Pediatr"},{"key":"820_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/life13071601","volume":"13","author":"SM McIntosh","year":"2023","unstructured":"McIntosh SM, Kerut C, Hollenshead PP, et al. Golimumab for polyarticular juvenile idiopathic arthritis and psoriatic arthritis: pharmacologic and clinical considerations. Life. 2023;13:1601.","journal-title":"Life"},{"key":"820_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.851532","volume":"9","author":"RA Moura","year":"2022","unstructured":"Moura RA, Fonseca JE. B cells on the stage of inflammation in juvenile idiopathic arthritis: leading or supporting actors in disease pathogenesis? Front Med (Lausanne). 2022;9:851532.","journal-title":"Front Med (Lausanne)"},{"key":"820_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40272-023-00618-2","volume":"26","author":"S Lokhandwala","year":"2024","unstructured":"Lokhandwala S, Townsend J, Ciurtin C. Existing and emerging targeted therapies in juvenile psoriatic arthritis: challenges and unmet needs. Paediatr Drugs. 2024;26:217\u201328.","journal-title":"Paediatr Drugs"},{"key":"820_CR7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/art.41390","volume":"72","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Schanberg LE, Kimura Y, et al. New medications are needed for children with juvenile idiopathic arthritis. Arthritis Rheumatol. 2020;72:1945\u201351.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"820_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/14712598.2024.2401148","volume":"24","author":"QY Su","year":"2024","unstructured":"Su QY, Gao HY, Duan YR, et al. The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target. Expert Opin Biol Ther. 2024;24(10):1119\u201332.","journal-title":"Expert Opin Biol Ther"},{"key":"820_CR9","unstructured":"Ustekinumab. Package insert. Janssen Pharmaceuticals Companies. 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/STELARA-pi.pdf."},{"key":"820_CR10","unstructured":"ClinicalTrials.gov. A study of ustekinumab or guselkumab in pediatric participants with active juvenile psoriatic arthritis (PSUMMIT-Jr). https:\/\/clinicaltrials.gov\/search?term=NCT05083182."},{"key":"820_CR11","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"820_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/art.23240","volume":"59","author":"ML Stoll","year":"2008","unstructured":"Stoll ML, Lio P, Sundel RP, Nigrovic PA. Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis. Arthritis Rheum. 2008;59:51\u20138.","journal-title":"Arthritis Rheum"},{"key":"820_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cpt.2033","volume":"109","author":"W Zhou","year":"2021","unstructured":"Zhou W, Hu C, Zhu Y, et al. Extrapolating pharmacodynamic effects from adults to pediatrics: a case study of ustekinumab in pediatric patients with moderate to severe plaque psoriasis. Clin Pharmacol Ther. 2021;109:131\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"820_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjd.19018","volume":"183","author":"S Philipp","year":"2020","unstructured":"Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u2265 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183:664\u201372.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"820_CR15","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1093\/ibd\/izy393.055","volume":"25","author":"JC Marini","year":"2019","unstructured":"Marini JC, Chun KY, Rebarchak S, et al. P049 Comparison of ustekinumab concentration assays and antibodies-to-ustekinumab assays. Inflamm Bowel Dis. 2019;25(Suppl 1):S24\u20135.","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"820_CR16","doi-asserted-by":"publisher","first-page":"S439","DOI":"10.1093\/ecco-jcc\/jjx180.776","volume":"12","author":"JC Marini","year":"2018","unstructured":"Marini JC, Gils A, Shankar G, et al. P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients. J Crohn\u2019s Colitis. 2018;12(Suppl 1):S439.","journal-title":"J Crohn\u2019s Colitis"},{"key":"820_CR17","first-page":"166","volume":"12","author":"X Zhu","year":"2013","unstructured":"Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12:166\u201374.","journal-title":"J Drugs Dermatol"},{"key":"820_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","volume":"63","author":"TF Tsai","year":"2011","unstructured":"Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63:154\u201363.","journal-title":"J Dermatol Sci"},{"key":"820_CR19","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","volume":"73","author":"I Landells","year":"2015","unstructured":"Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73:594\u2013603.","journal-title":"J Am Acad Dermatol"},{"key":"820_CR20","unstructured":"Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: NHANES III. https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/nhanes3\/default.aspx."},{"key":"820_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.cct.2016.03.002","volume":"47","author":"A England","year":"2016","unstructured":"England A, Wade K, Smith PB, Berezny K, Laughon M, Best Pharmaceuticals for Children Act-Pediatric Trials Network Administrative Core Committee. Optimizing operational efficiencies in early phase trials: the Pediatric Trials Network experience. Contemp Clin Trials. 2016;47:376\u201382.","journal-title":"Contemp Clin Trials"},{"key":"820_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40272-022-00533-y","volume":"24","author":"JH Leu","year":"2022","unstructured":"Leu JH, Shiff NJ, Clark M, et al. Intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis and subcutaneous ustekinumab in patients with juvenile psoriatic arthritis: extrapolation of data from studies in adults and adjacent pediatric populations. Paediatr Drugs. 2022;24:699\u2013714.","journal-title":"Paediatr Drugs"},{"key":"820_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/0091270008329556","volume":"49","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49:162\u201375.","journal-title":"J Clin Pharmacol"},{"key":"820_CR24","unstructured":"Pediatric Trials Network: Results At-A-Glance; PTN studies. https:\/\/pediatrictrials.org\/."},{"key":"820_CR25","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1128\/AAC.02374-13","volume":"58","author":"A Tremoulet","year":"2014","unstructured":"Tremoulet A, Le J, Poindexter B, et al. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. Antimicrob Agents Chemother. 2014;58:3013\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"820_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/clpt.2014.134","volume":"96","author":"D Gonzalez","year":"2014","unstructured":"Gonzalez D, Melloni C, Yogev R, et al. Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. Clin Pharmacol Ther. 2014;96:429\u201337.","journal-title":"Clin Pharmacol Ther"},{"key":"820_CR27","doi-asserted-by":"publisher","first-page":"e02014","DOI":"10.1128\/AAC.02014-16","volume":"61","author":"MJ Smith","year":"2017","unstructured":"Smith MJ, Gonzalez D, Goldman JL, et al. Pharmacokinetics of clindamycin in obese and nonobese children. Antimicrob Agents Chemother. 2017;61:e02014-e2016.","journal-title":"Antimicrob Agents Chemother"},{"key":"820_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3899\/jrheum.200124","volume":"96","author":"LC Coates","year":"2020","unstructured":"Coates LC, Merola JF, Grieb SM, Mease PJ, Duffin KC. Methotrexate in psoriasis and psoriatic arthritis. J Rheumatol Suppl. 2020;96:31\u20135.","journal-title":"J Rheumatol Suppl"},{"key":"820_CR29","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1093\/rheumatology\/kead177","volume":"62","author":"SM Mojtahed Poor","year":"2023","unstructured":"Mojtahed Poor SM, Henke M, Ulsh\u00f6fer T, et al. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate. Rheumatology (Oxford). 2023;62:3993\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"820_CR30","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2665-9913(22)00329-0","volume":"5","author":"M Koehm","year":"2023","unstructured":"Koehm M, Rossmanith T, Foldenauer AC, et al. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Lancet Rheumatol. 2023;5:e14-23.","journal-title":"Lancet Rheumatol"},{"key":"820_CR31","doi-asserted-by":"publisher","first-page":"830","DOI":"10.5414\/CPP48830","volume":"48","author":"YW Zhu","year":"2010","unstructured":"Zhu YW, Mendelsohn A, Pendley C, Davis HM, Zhou H. Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. Int J Clin Pharmacol Ther. 2010;48:830\u201346.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"820_CR32","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675\u201384.","journal-title":"Lancet"},{"key":"820_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/03009742.2025.2465014","volume":"54","author":"B Firlatan","year":"2025","unstructured":"Firlatan B, Kart Bayram GS, Ayan G, et al. Sex distribution in psoriatic arthritis: a systematic literature review. Scand J Rheumatol. 2025;54:192\u20137.","journal-title":"Scand J Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00820-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00820-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00820-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:52:33Z","timestamp":1768834353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00820-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["820"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00820-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amy S. Paller is an investigator for AbbVie, BioMendics, Dermavant, Eli Lilly, Incyte, Johnson & Johnson, Regeneron, and UCB; is a consultant for Abeona, Arcutis, BioCryst, Boehringer-Ingelheim, Castle Creek, Chiesi, Dermavant, Johnson & Johnson, Krystal, LEO, Lilly, L\u2019Oreal, MoonLake Immunotherapeutics, Pelthos, Quoin, Regeneron, and Sanofi; and serves on the data safety monitoring boards of AbbVie, Abeona, BioCryst, Daiichi Sankyo, and Galderma. Corey J. Bishop, Jocelyn H. Leu, Katherine Berezny, Kathleen G. Lomax, Renping Zhang, Sophia G. Liva, and Valerie Smith are employees of Johnson & Johnson and own company stock\/stock options. Edwin Lam was an employee of Johnson & Johnson when this work was conducted, their current affiliation is Biogen. Hermine I. Brunner reports having received contributions in the past 3\u00a0years from AbbVie, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Janssen, UCB, Novartis, and Pfizer (this funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment to third parties); reports having received consulting fees from AbbVie, Astra Zeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, EMD Serono, GlaxoSmithKline, F. Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharm, UCB, and Sanofi; and has served on speakers\u2019 bureaus for GlaxoSmithKline, Novartis, and Roche. Lucia Z. Diaz is an investigator for Janssen and Regeneron. Lara Wine Lee has received consulting fees from AbbVie, Chiesi, Kimberly-Clark Corporation, Krystal Biotech, and Nobelpharma; served as an investigator for AbbVie, Amryt Pharma, Arcutis Biotherapeutics, Bristol Myers Squibb, Castle Creek Biosciences, Celgene Corporation, Galderma, Incyte, Janssen, Kiniksa Pharmaceuticals, Eli Lilly, Mayne Pharma, Novartis, Pfizer, Regeneron, Sanofi, Target Pharma, Trevi Therapeutics, and UCB; and has served as an advisory board member for Eli Lilly, Novartis, Pfizer, and Regeneron. Cory Rubin reports being an investigator for AbbVie, Apollo Therapeutics, Bristol Myers Squibb, Bluefin, Cara Therapeutics, Castle Biosciences, CorEvitas, DermTech, Horizon Therapeutics, Incyte, Janssen, LEO Pharma, MoonLake Therapeutics, Pfizer, Regeneron, Sanofi, and Union Therapeutics; a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, Sanofi, and UCB; and a speaker for AbbVie, Amgen, Boehringer Ingelheim, Castle Biosciences, Dermavant, DermTech, Galderma, Incyte, LEO Pharma, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB, and Verrica. Ruy Carrasco reports being on the board of directors for BEN AI Inc. and owns company stocks. Lisa Imundo and Azadeh Majlessi have no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. The study protocol, protocol amendments, and other relevant documents were reviewed and approved by the institutional review board (IRB) of the participating site (Lurie Children\u2019s Hospital of Chicago IRB, University of Cincinnati Medical IRB, Columbia University Medical Center IRB, Akron Children\u2019s Hospital IRB) or the central IRB (Sterling IRB; IRB ID: 9300-*MASTER) before the study was initiated. Participants or their legally designated representatives provided their written consent to participate in the study after having been informed about the nature and purpose of the study, participation\/termination conditions, and risks and benefits.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}